[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612792":3},{"organization":4,"outcomesModule":7,"designInfo":14,"detailedDescription":17,"studyPopulation":18,"armGroups":19,"interventions":25,"overallOfficials":13,"centralContacts":31,"locations":37,"responsibleParty":53,"collaborators":55,"id":58,"slug":13,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":59,"sex":65,"minAge":66,"maxAge":13,"enrollmentInfo":67,"targetDuration":13,"studyType":70,"phases":13,"briefSummary":71,"conditions":72,"keywords":13,"overallStatus":40,"whyStopped":13,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Regina Elena Cancer Institute","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":13},[9],{"measure":10,"description":11,"timeFrame":12},"Feasibility of organoid generation","The feasibility of generating endometrial carcinoma organoids from tumor tissue will be assessed by analyzing the success rate in organoid generation, expressed as a percentage.","42 months",null,{"allocation":13,"interventionModel":13,"interventionModelDescription":13,"primaryPurpose":13,"observationalModel":15,"timePerspective":16,"maskingInfo":13},"COHORT","PROSPECTIVE","The prospective study involves the collection and freezing of biological samples at the IRE Translational Oncology Research Unit. Collecting and using:\n\n* Fresh tissue: tumor and peritumor tissue from the same patient, obtained surgically at participating centers, will be collected under the supervision of a dedicated pathologist, sent to the IRE Translational Oncology Research Unit, and frozen. The collected tissue will be processed and used to perform gene expression profiling using RNAseq and WES and to generate organoids.\n* Blood (Serum and PBMCs) - A blood sample (EmoT0) will also be collected for each patient before surgery. This sample will be used to prepare serum for aliquoting\u002Ffreezing, and peripheral blood mononuclear cells (PBMCs). These will also be sent, frozen, and stored at the IRE Translational Oncology Research Unit. These will be used to evaluate the organoids' response to immunotherapy treatments through coculture experiments.\n\nOnly biological material whose availability and suitability are guaranteed will be used to archive appropriate material as required by law. It will then be sent to the research laboratories of the IRE Translational Oncology Research Unit and will be used for genomic analysis and the generation of organoids.","Patients with a histological diagnosis of endometrioid endometrial cancer at any stage of the disease.",[20],{"label":21,"type":13,"description":22,"interventionNames":23},"Patients with endometrial cancer of the endometrioid histology at any stage of the disease.","Patients aged 18 years and older with a histological diagnosis of endometrial cancer of the endometrioid histology at any stage of disease (FIGO I-IV), recurrence\u002Fmetastasis from endometrial endometrioid cancer, who are candidates for surgery or hysterectomy and who will undergo surgery after signing an informed consent form, will be prospectively recruited.",[24],"Genetic: Generation of organoids from endometrial tumor tissue collected during surgery, performed according to standard clinical practice",[26],{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":13},"GENETIC","Generation of organoids from endometrial tumor tissue collected during surgery, performed according to standard clinical practice","Creation of endometrial carcinoma organoids from tumor tissue from extramural structures, verifying the feasibility of organoid generation. Evaluate the impact of sample transport and storage conditions on the success of the process, considering the challenges associated with preserving tissue integrity.",[21],[32],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},"Giovanni Blandino, Medical Doctor","CONTACT","+39 0652662911","giovanni.blandino@ifo.it",[38],{"facility":39,"status":40,"city":41,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"IRCCS National Cancer Institute \"Regina Elena\"","RECRUITING","Roma","00144","Italy","IT",{"type":46,"coordinates":47},"Point",[48,49],11.10642,44.99364,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":13,"email":36},{"type":54,"investigatorFullName":13,"investigatorTitle":13,"investigatorAffiliation":13,"oldNameTitle":13,"oldOrganization":13},"SPONSOR",[56],{"name":57,"class":6},"Azienda Ospedaliera Universitaria Integrata Verona","100612792",false,"NCT07258186","Generation of Endometrial Carcinoma Organoids","Feasibility Study of the Generation of Endometrial Carcinoma Organoids From Tumor Samples Transferred From Extramural Facilities","organoids endo","Inclusion Criteria:\n\n* Age \\>18 years;\n* Patients with a histological diagnosis of: endometrial cancer, endometrioid histology, any stage of disease (FIGO I-IV), recurrence\u002Fmetastasis from endometrial endometrioid cancer, and candidates for surgery and\u002For hysterectomy;\n* Written informed consent (study participation and data processing) must be obtained in person and\u002For through a legal representative\u002Fguardian\u002Fsupport administrator\u002Fwitness, before any study-specific procedure is performed.\n\nExclusion Criteria:\n\n* Comorbidities not controlled with adequate medical therapy;\n* Endometrial cavity infections (pyometra);\n* Synchronous tumors;\n* Neoadjuvant treatments;\n* Previous radiation treatments to the pelvic region.","FEMALE","18 Years",{"count":68,"type":69},20,"ESTIMATED","OBSERVATIONAL","A prospective pilot genetic study to evaluate the feasibility of generating organoids from endometrial tumor tissue collected during surgery, performed according to standard clinical practice. Samples will be collected from collaborating extramural facilities, with the aim of analyzing the impact of transport on tissue viability and the success of organoid culture. This study is for exploratory purposes only, without altering the diagnostic and therapeutic pathways of the participants.",[73],"Endometrial Cancer","2025-11-27",{"date":76,"type":77},"2025-12-02","ACTUAL",{"date":79,"type":77},"2025-03-23",{"date":81,"type":69},"2028-09-23",{"name":5,"class":6},1]